

Discrimination between oral corticosteroid-treated and oral corticosteroid-non-treated severe asthma patients by an electronic nose platform

Original

Discrimination between oral corticosteroid-treated and oral corticosteroid-non-treated severe asthma patients by an electronic nose platform / Santini, G.; DI CARLO, Stefano; Benso, Alfredo; Mores, N.; Brinkman, P.; Valente, S.; Montuschi, Paolo; Macagno, F.; Wagener, A. H.; Bansal, A. T.; Pandis, I.; Knobel, H. H.; Vink, A. J.; Rattray, N.; Santonico, M.; Pennazza, G.; Guo, Y. K.; Horvath, I.; Djukanovic, R.; Polosa, R.; Sousa, A. R.; Corfield, J.; Rowe, A.; Fowler, S. J.; Chanez, P.; Chung, K. F.; Sterk, P. J.; Montuschi, P.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 1399-3003. - ELETTRONICO. - 44:Suppl. 58 P2054(2014).

Availability:

This version is available at: 11583/2584957 since: 2016-10-10T13:28:38Z

Publisher:

European Respiratory Society

Published

DOI:

Terms of use:

openAccess

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)

VOLUME 44 / SUPPLEMENT 58 / SEPTEMBER 2014

EUROPEAN RESPIRATORY *journal*

OFFICIAL SCIENTIFIC JOURNAL OF THE ERS

Abstracts / *24th International Congress*
Munich, Germany 6 –10 September 2014

Online ISSN: 1399-3003



ERS

EUROPEAN
RESPIRATORY
SOCIETY

every breath counts

Copyright for individual abstracts remains with the authors.

This abstract supplement has been produced electronically by the European Respiratory Society. The European Respiratory Society is not responsible for errors or omissions in content. The ideas and opinions expressed in this publication do not necessarily reflect those of Coe-Truman and the European Respiratory Society. Products mentioned in this publication should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The European Respiratory Society assumes no responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in these abstracts. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. An effort has been made to check generic and trade names, and to verify drug doses. The ultimate responsibility, however, lies with the prescribing physician. Please convey any errors to scientific@ersnet.org.

Citations should be made in the following way: **Authors. Title. Eur Respir J 2014; 44: Suppl. 58, abstract number.**



Table Of Content

240. Systemic and airway biomarkers 2

2054: Discrimination between oral corticosteroid-treated and oral corticosteroid-non-treated severe asthma patients by an electronic nose platform 2



240. Systemic and airway biomarkers

2054

Discrimination between oral corticosteroid-treated and oral corticosteroid-non-treated severe asthma patients by an electronic nose platform

Giuseppe Santini¹, Stefano Di Carlo², Alfredo Benso², Nadia Mores¹, Paul Brinkman³, Salvatore Valente¹, Paolo Montuschi², Francesco Macagno¹, Ariane H. Wagener³, Aruna T. Bansal⁴, Ioannis Pandis⁵, Hugo H. Knobel⁶, Anton J. Vink⁶, Nicholas Rattray⁷, Marco Santonico⁸, Giorgio Pennazza⁸, Yi-Ke Guo⁵, Ildiko Horvath⁹, Ratko Djukanovic¹⁰, Riccardo Polosa¹¹, Ana R. Sousa¹², Julie Corfield¹³, Anthony Rowe¹⁴, Stephen J. Fowler¹⁵, Pascal Chanez¹⁶, Kian Fan Chung⁵, Pater J. Sterk³, Paolo Montuschi¹

¹Pharmacology, Catholic University of the Sacred Heart, Rome, Italy

Rationale: Some severe asthma patients require oral corticosteroids (OCS) likely due to greater disease severity. Exhaled molecular markers can provide phenotypic information in asthma. **Objectives:** Determine whether patients on OCS (OCS⁺) have a different breathprint compared with those who were not on OCS (OCS⁻); determine the classification accuracy of eNose as compared to FEV₁ % pred, % sputum eosinophils, and exhaled nitric oxide (FENO). **Methods:** This was a cross-sectional analysis of the U-BIOPRED cohort. Severe asthma was defined by IMI-criteria [Bel Thorax 2011]. OCS⁺ patients had daily OCS. OCS⁻ patients had never had OCS and were on maintenance inhaled fluticasone equivalent >1000 µg/day. Exhaled volatile organic compounds trapped on adsorption tubes were analysed by centralized eNose platform (Owlstone Lonestar, Cyranose 320, Comon Invent, Tor Vergata TEN) including a total of 190 sensors, t test was used for comparing groups and support vector machine with leave-one-out cross-validation as a classifier. **Results:** 33 OCS⁺ (age 55±11yr, mean±SD, 52% female, 27% smokers, pre-bronchodilator FEV₁ 64.1±24% pred) and 40 OCS⁻ severe asthma patients (age 54±15yr, mean±SD, 55% female, 35% smokers, pre-bronchodilator FEV₁ 61.8±24% pred) were studied. Sensor by sensor analysis showed that 56 sensors provided different mean values (change in sensor resistance or frequency) between groups (P<0.05). Accuracy of classification was as follows: eNose 71% (n=73), FENO 71% (n=70), FEV₁ 62% (n=73) and sputum eosinophils 59% (n=37). **Conclusions:** Preliminary results suggest OCS⁺ and OCS⁻ severe asthma patients can be distinguished by an eNose platform.